WHAT IS CLAIMED IS:

1. A compound of the formula:



in which A is a moiety of the formula



where the dotted line represents optional unsaturation,

or the cycloalkenyl moiety



;

R_1 is hydrogen or alkyl of 1 to 6 carbon atoms;

R_2 is alkyl of 1 to 6 carbon atoms;

R_4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanoyl of 2 to 7 carbon atoms;

R_5 and R_6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or, when taken together, methylene dioxy;

R_7 is hydrogen or alkyl of 1 to 6 carbon atoms; and

n is one of the integers 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 in which in which R_1 is hydrogen or alkyl of 1 to 3 carbon atoms; R_2 is alkyl of 1 to 3 carbon atoms; R_5 is hydrogen, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkyl of 1 to 3 carbon atoms; R_6 is alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkanoyloxy of 2 to 3 carbon atoms; R_7 is hydrogen or alkyl of 1 to 3 carbon atoms; or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 2 in which R_5 and R_6 are in meta or para positions and n is 2.

4. The compound of Claim 1 which is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

5. The compound of Claim 1 which is 1-(α-[(dimethylamino)methyl]benzyl)cyclohexanol or a pharmaceutically acceptable salt thereof.

6. The compound of Claim 1 which is 1-(α-[methylamino)-methyl]benzyl)cyclohexanol or a pharmaceutically acceptable salt thereof.

7. The compound of Claim 1 which is 1-[1-(4-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 1 which is 1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

9. The compound of Claim 37 which is 1-[1-(4-bromophenyl-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

10. The compound of Claim 37 which is 1-[1-(3-bromophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 37 which is 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

12. The compound of Claim 37 which is 1-[1-(2-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

13. The compound of Claim 37 which is 1-[1-(3,4-dichlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

14. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexene or a pharmaceutically acceptable salt thereof.

15. The compound of Claim 37 which is 1-[2-(dimethylamino)-1-(3-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

16. The compound of Claim 37 which is 1-[1-(3,4-dimethoxyphenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

17. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(4-trifluoromethylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

18. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

19. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(4-methylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

20. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohex-2-en-1-ol or a pharmaceutically acceptable salt thereof.

21. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

22. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(3-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

23. The compound of Claim 1 which is 1-[1-(4-aminophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

24. The compound of Claim 1 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclopentanol or a pharmaceutically acceptable salt thereof.

25. The compound of Claim 37 which is 1-[1-(4-nitrophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

26. The compound of Claim 37 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cycloheptanol or a pharmaceutically acceptable salt thereof.

27. The compound of Claim 37 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclooctanol or a pharmaceutically acceptable salt thereof.

28. The compound of Claim 37 which is 1-[2-(dimethylamino)-1-(3-bromo-4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

29. The compound of Claim 37 which is 1-[1-(3,4-dibromophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

30. The compound of Claim 37 which is 1-[(2-dimethylamino)-1-(3-methylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

31. The compound of Claim 37 which is 1-[1-(4-bromophenyl-2-(dimethylamino)ethyl]cyclobutanol or a pharmaceutically acceptable salt thereof.

32. The compound of Claim 37 which is 1-[2-(dimethylamino)-1-(3-methoxyphenyl)ethyl]cyclopentanol or a pharmaceutically acceptable salt thereof.

END 49

14
~~33~~. The compound of Claim ~~1~~ 1 which is 1-[2-[1-(dimethylamino)-2-(4-methoxyphenyl)propyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

34. A compound of the formula



in which the dotted line represents optional unsaturation,

R_4 is hydrogen or alkyl of 1 to 6 carbon atoms;

R_5 and R_6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, aralkoxy of 7 to 9 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, alkylmercapto of 1 to 6 carbon atoms, halo or trifluoromethyl;

R_7 is hydrogen or alkyl of 1 to 6 carbon atoms; and

n is one of the integers 0, 1, 2, 3 or 4.

35. A compound of the formula



in which the dotted line represents optional unsaturation,

R_1 is hydrogen or alkyl of 1 to 6 carbon atoms;

R_2 is alkyl of 1 to 6 carbon atoms;

R_4 is hydrogen or alkyl of 1 to 6 carbon atoms;

R_5 and R_6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, aralkoxy of 7 to 9 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, alkylmercapto of 1 to 6 carbon atoms, N-protected amino, halo, trifluoromethyl, or when taken together, methylenedioxy;

R_7 is hydrogen or alkyl of 1 to 6 carbon atoms;

n is one of the integers 0, 1, 2, 3 or 4.

36. A process for the production of a compound of the formula:



in which A is a moiety of the formula



where the dotted line represents optional unsaturation,

or the cycloalkenyl moiety



R_1 is hydrogen or alkyl of 1 to 6 carbon atoms;

R_2 is alkyl of 1 to 6 carbon atoms;

R_4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanoyl of 2 to 7 carbon atoms;

R_5 and R_6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or, when taken together, methylene dioxy;

R_7 is hydrogen or alkyl of 1 to 6 carbon atoms; and

n is one of the integers 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof, which comprises

(a) reducing an amide of the formula



in which R_1, R_2, R_7 and n are defined, supra, the dotted line represents optional unsaturation, R_4 is hydrogen or alkyl of 1 to 6 carbon atoms and R_5 and R_6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, aralkoxy of 7 to 9 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, alkylmercapto of 1 to 6 carbon atoms, N-protected amino, halo, trifluoromethyl, or when taken together, methylenedioxy, with the proviso that said reduction is selectively performed with aluminum hydride when the dotted lines represent ring unsaturation;

or (b) reducing a nitrile of the formula



in which R_4, R_5, R_6, R_7, n and the dotted lines are defined under (a), supra, with the exception that R_5 and R_6 are not methylenedioxy, to produce an amine, followed by N-mono- or -di-alkylation and optionally

(1) acylating the product with an active derivative of formic acid or an alkanoic acid containing from 2 to 7 carbon atoms to introduce the R_4 group or an R_1 and/or R_2 acyl group which is subsequently reduced to afford an R_1 and/or R_2 alkyl group;

(2) deprotecting said N-protected amino substituent to obtain the free amine, mono- or di-alkylating or acylating the amine or diazotizing the amino group and displacing the diazolate salt with a nitrite or a nitrile;

(3) displacing a halo substituent with a nitrile;

(4) dehydrating to introduce unsaturation into the cycloalkanyl ring

or (c) subjecting an aldehyde of the formula



in which R_4, R_5, R_6, R_7, n and the dotted lines are defined under (a), supra, (1) to amination with hydroxylamine, ammonia, a pri-

mary alkylamine or a secondary alkylamine followed by reduction or (2) to reductive amination with an amine of the formula HNR_1R_2 and a reducing agent

or (d) subjecting a compound of the formula



in which R_4, R_5, R_6, R_7, n and the dotted lines are defined under (a), supra, and Z is a leaving group to reaction with ammonia or HNR_1R_2 where in R_1 and R_2 are defined in (a), supra, followed by alkylation of the product obtained in the reaction with ammonia.

Add 7
B1